Sacubitril-Valsartan in Patients with Ischemic Cardiomyopathy Undergoing Off-Pump Coronary Artery Bypass Grafting-Is It Safe?

Sacubitril-valsartan has been used selectively in patients undergoing coronary artery bypass grafting (CABG) and ischemic cardiomyopathy due to safety concerns. The aim of this prospective observational study was to assess the safety profile of sacubitril-valsartan in patients with reduced ejection fraction (EF <40%) undergoing CABG. Primary outcome was tolerability and safety profile. Thirty consecutive patients undergoing CABG with EF <40% were included. No mortality or readmissions occurred during 6 months follow-up. One (3.3%) patient experienced hypotension requiring discontinuation. Mild (8.9%) elevation in blood urea nitrogen, p = 0.35; along with a significant increase in serum creatinine (0.12mg/DL), p = 0.02; and potassium (0.23 mmol/L), p 0.003 was seen during follow-up. Sacubitril-valsartan is well tolerated in patients with reduced EF undergoing CABG.

Automated summary

The aim of this study was to assess the safety profile of sacubitril-valsartan in patients with reduced ejection fraction undergoing CABG. The results showed that sacubitril-valsartan was well tolerated in patients, with no deaths or readmissions occurring during the 6-month follow-up period. However, one patient experienced hypotension requiring discontinuation, and there were mild elevations in blood urea nitrogen, serum creatinine, and potassium levels.